|
|
| (13 intermediate revisions by 4 users not shown) |
| Line 3: |
Line 3: |
| {{CMG}} | | {{CMG}} |
|
| |
|
| ==ACCF/AHA/SCAI 2011 Guidelines for Percutaneous Coronary Intervention: Dual Antiplatelet Therapy Compliance and Stent Thrombosis<ref name="pmid22070837">{{cite journal |author=Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA, Hollenberg SM, Khot UN, Lange RA, Mauri L, Mehran R, Moussa ID, Mukherjee D, Nallamothu BK, Ting HH |title=2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: Executive Summary A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions |journal=[[Journal of the American College of Cardiology]] |volume=58 |issue=24 |pages=2550–83 |year=2011 |month=December|pmid=22070837|doi=10.1016/j.jacc.2011.08.006|url=http://linkinghub.elsevier.com/retrieve/pii/S0735-1097(11)02875-0|accessdate=2011-12-08|url=http://content.onlinejacc.org/cgi/reprint/58/24/2550.pdf|PDF}}</ref> (DO NOT EDIT)== | | ==2011 ACCF/AHA/SCAI Guidelines for Percutaneous Coronary Intervention and 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery (DO NOT EDIT)<ref name="pmid22070837">{{cite journal|author=Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA, Hollenberg SM, Khot UN, Lange RA, Mauri L, Mehran R, Moussa ID, Mukherjee D, Nallamothu BK, Ting HH |title=2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: Executive Summary A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions |journal=[[Journal of the American College of Cardiology]]|volume=58 |issue=24 |pages=2550–83 |year=2011|month=December|pmid=22070837|doi=10.1016/j.jacc.2011.08.006|url=http://linkinghub.elsevier.com/retrieve/pii/S0735-1097(11)02875-0|accessdate=2011-12-08|url=http://content.onlinejacc.org/cgi/reprint/58/24/2550.pdf|PDF}}</ref><ref name="pmid22064599">{{cite journal| author=Hillis LD, Smith PK, Anderson JL, Bittl JA, Bridges CR, Byrne JG et al.| title=2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. | journal=Circulation | year= 2011 | volume= | issue= | pages= | pmid=22064599 | doi=10.1161/CIR.0b013e31823c074e | pmc= |url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22064599 }} </ref>== |
| | ===Dual Antiplatelet Therapy Compliance and Stent Thrombosis (DO NOT EDIT) <ref name="pmid22070837">{{cite journal|author=Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA, Hollenberg SM, Khot UN, Lange RA, Mauri L, Mehran R, Moussa ID, Mukherjee D, Nallamothu BK, Ting HH |title=2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: Executive Summary A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions |journal=[[Journal of the American College of Cardiology]]|volume=58 |issue=24 |pages=2550–83|year=2011|month=December|pmid=22070837|doi=10.1016/j.jacc.2011.08.006|url=http://linkinghub.elsevier.com/retrieve/pii/S0735-1097(11)02875-0|accessdate=2011-12-08|url=http://content.onlinejacc.org/cgi/reprint/58/24/2550.pdf|PDF}}</ref><ref name="pmid22064599">{{cite journal| author=Hillis LD, Smith PK, Anderson JL, Bittl JA, Bridges CR, Byrne JG et al.| title=2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. | journal=Circulation | year= 2011 | volume= | issue= | pages= | pmid=22064599 | doi=10.1161/CIR.0b013e31823c074e | pmc= |url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22064599 }} </ref>=== |
|
| |
|
| {|class="wikitable" | | {|class="wikitable" |
| |-
| |
| | colspan="1" style="text-align:center; background:LightGreen"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class I]]
| |
|
| |
|
| |- | | |- |
| | bgcolor="LightGreen"|<nowiki>"</nowiki>'''1.''' Before implantation of [[Drug eluting stent|drug eluting stent (DES)]], the interventional cardiologist should discuss with the patient the need for and duration of [[Dual antiplatelet therapy|dual antiplatelet therapy (DAPT)]] and the ability of the patient to comply with and tolerate [[Dual antiplatelet therapy|DAPT]].<ref name="pmid17148711">{{cite journal|author=Eisenstein EL, Anstrom KJ, Kong DF, Shaw LK, Tuttle RH, Mark DB, Kramer JM, Harrington RA, Matchar DB, Kandzari DE, Peterson ED, Schulman KA, Califf RM |title=Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation |journal=[[JAMA : the Journal of the American Medical Association]] |volume=297 |issue=2 |pages=159–68 |year=2007 |month=January|pmid=17148711 |doi=10.1001/jama.297.2.joc60179 |url=http://jama.ama-assn.org/cgi/pmidlookup?view=long&pmid=17148711 |accessdate=2011-12-08}}</ref> ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])''<nowiki>"</nowiki> | | |colspan="1" style="text-align:center; background:LightCoral"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class III]] (Harm) |
|
| |
|
| |- | | |- |
| | bgcolor="LightGreen"|<nowiki>"</nowiki>'''2.''' [[Drug eluting stent|Drug eluting stent (DES)]] are useful as an alternative to [[Bare metal stent|BMS]] to reduce the risk of [[restenosis]] in cases in which the risk of restenosis is increased and the patient is likely to be able to tolerate and comply with prolonged [[Dual antiplatelet therapy|dual antiplatelet therapy (DAPT)]]. For elective [[ST elevation myocardial infarction primary percutaneous coronary intervention|PCI]] <ref name="pmid14523139">{{cite journal|author=Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, Kuntz RE |title=Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery |journal=[[The New England Journal of Medicine]] |volume=349 |issue=14 |pages=1315–23 |year=2003 |month=October |pmid=14523139|doi=10.1056/NEJMoa035071 |url=http://dx.doi.org/10.1056/NEJMoa035071|accessdate=2011-12-08}}</ref><ref name="pmid15078803">{{cite journal |author=Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, Popma JJ, Russell ME |title=One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial |journal=[[Circulation]] |volume=109 |issue=16 |pages=1942–7|year=2004 |month=April |pmid=15078803 |doi=10.1161/01.CIR.0000127110.49192.72|url=http://circ.ahajournals.org/cgi/pmidlookup?view=long&pmid=15078803|accessdate=2011-12-08}}</ref><ref name="pmid18815397">{{cite journal |author=Mauri L, Silbaugh TS, Garg P, Wolf RE, Zelevinsky K, Lovett A, Varma MR, Zhou Z, Normand SL |title=Drug-eluting or bare-metal stents for acute myocardial infarction |journal=[[The New England Journal of Medicine]]|volume=359 |issue=13 |pages=1330–42 |year=2008 |month=September |pmid=18815397|doi=10.1056/NEJMoa0801485 |url=http://dx.doi.org/10.1056/NEJMoa0801485|accessdate=2011-12-08}}</ref><ref name="pmid19420364">{{cite journal |author=Stone GW, Lansky AJ, Pocock SJ, Gersh BJ, Dangas G, Wong SC, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Möckel M, Ochala A, Kellock A, Parise H, Mehran R |title=Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction |journal=[[The New England Journal of Medicine]] |volume=360|issue=19 |pages=1946–59 |year=2009 |month=May |pmid=19420364 |doi=10.1056/NEJMoa0810116|url=http://dx.doi.org/10.1056/NEJMoa0810116 |accessdate=2011-12-08}}</ref><ref name="pmid21872918">{{cite journal |author=Mehilli J, Pache J, Abdel-Wahab M, Schulz S, Byrne RA, Tiroch K, Hausleiter J, Seyfarth M, Ott I, Ibrahim T, Fusaro M, Laugwitz KL, Massberg S, Neumann FJ, Richardt G, Schömig A, Kastrati A |title=Drug-eluting versus bare-metal stents in saphenous vein graft lesions (ISAR-CABG): a randomised controlled superiority trial |journal=[[Lancet]] |volume=378|issue=9796 |pages=1071–8 |year=2011 |month=September |pmid=21872918|doi=10.1016/S0140-6736(11)61255-5|url=http://linkinghub.elsevier.com/retrieve/pii/S0140-6736(11)61255-5|accessdate=2011-12-08}}</ref> ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: A]])''; for [[Unstable angina / non ST elevation myocardial infarction|UA/NSTEMI]] <ref name="pmid18815397">{{cite journal |author=Mauri L, Silbaugh TS, Garg P, Wolf RE, Zelevinsky K, Lovett A, Varma MR, Zhou Z, Normand SL |title=Drug-eluting or bare-metal stents for acute myocardial infarction |journal=[[The New England Journal of Medicine]] |volume=359 |issue=13 |pages=1330–42|year=2008 |month=September |pmid=18815397 |doi=10.1056/NEJMoa0801485|url=http://dx.doi.org/10.1056/NEJMoa0801485 |accessdate=2011-12-08}}</ref> ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])''; for [[ST elevation myocardial infarction|STEMI]] <ref name="pmid18815397">{{cite journal |author=Mauri L, Silbaugh TS, Garg P, Wolf RE, Zelevinsky K, Lovett A, Varma MR, Zhou Z, Normand SL |title=Drug-eluting or bare-metal stents for acute myocardial infarction |journal=[[The New England Journal of Medicine]] |volume=359|issue=13 |pages=1330–42 |year=2008 |month=September |pmid=18815397 |doi=10.1056/NEJMoa0801485|url=http://dx.doi.org/10.1056/NEJMoa0801485 |accessdate=2011-12-08}}</ref><ref name="pmid19420364">{{cite journal |author=Stone GW, Lansky AJ, Pocock SJ, Gersh BJ, Dangas G, Wong SC, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Möckel M, Ochala A, Kellock A, Parise H, Mehran R |title=Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction |journal=[[The New England Journal of Medicine]] |volume=360 |issue=19 |pages=1946–59|year=2009 |month=May |pmid=19420364 |doi=10.1056/NEJMoa0810116|url=http://dx.doi.org/10.1056/NEJMoa0810116 |accessdate=2011-12-08}}</ref><ref name="pmid20872982">{{cite journal |author=Pan XH, Chen YX, Xiang MX, Xu G, Wang JA |title=A meta-analysis of randomized trials on clinical outcomes of paclitaxel-eluting stents versus bare-metal stents in ST-segment elevation myocardial infarction patients |journal=[[Journal of Zhejiang University. Science. B]] |volume=11 |issue=10 |pages=754–61 |year=2010 |month=October|pmid=20872982 |pmc=2950236 |doi=10.1631/jzus.B0900302 |url=http://www.zju.edu.cn/jzus/article.php?doi=10.1631/jzus.B0900302 |accessdate=2011-12-08}}</ref><ref name="pmid20978561">{{cite journal|author=Hao PP, Chen YG, Wang XL, Zhang Y |title=Efficacy and safety of drug-eluting stents in patients with acute ST-segment-elevation myocardial infarction: a meta-analysis of randomized controlled trials |journal=[[Texas Heart Institute Journal / from the Texas Heart Institute of St. Luke's Episcopal Hospital, Texas Children's Hospital]] |volume=37 |issue=5 |pages=516–24 |year=2010|pmid=20978561 |pmc=2953216 |doi= |url= |accessdate=2011-12-08}}</ref><ref name="pmid21262083">{{cite journal |author=Suh HS, Song HJ, Choi JE, Jang EJ, Son HJ, Lee SM, Kim JS, Choi D |title=Drug-eluting stents versus bare-metal stents in acute myocardial infarction: A systematic review and meta-analysis |journal=[[International Journal of Technology Assessment in Health Care]] |volume=27 |issue=1 |pages=11–22 |year=2011 |month=January |pmid=21262083|doi=10.1017/S0266462310001340 |url=http://journals.cambridge.org/abstract_S0266462310001340|accessdate=2011-12-08}}</ref> ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: A]])''.<nowiki>"</nowiki> | | |bgcolor="LightCoral"|<nowiki>"</nowiki>'''1.'''[[PCI]] with coronary stenting (BMS or DES) should not be performed if the patient is not likely to be able to tolerate and comply with dual [[antiplatelet]] therapy (DAPT) for the appropriate duration of treatment based on the type of [[stent]] implanted.<ref>Grines CL, Bonow RO, Casey DE Jr., et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. J Am Coll Cardiol. 2007; 49: 734– 9. </ref><ref>Leon MB, Baim DS, Popma JJ, et al., Stent Anticoagulation Restenosis Study Investigators. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. N Engl J Med. 1998; 339: 1665– 71.</ref><ref>Mauri L, Hsieh WH, Massaro JM, et al. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med. 2007; 356: 1020– 9.</ref><ref> McFadden EP, Stabile E, Regar E, et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet. 2004; 364: 1519– 21.</ref> ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])''<nowiki>"</nowiki> |
|
| |
|
| |-
| |
| | bgcolor="LightGreen"|<nowiki>"</nowiki>'''3.''' [[Balloon angioplasty]] or [[Bare metal stent|BMS]] should be used in patients with high bleeding risk, inability to comply with 12 months of [[Dual antiplatelet therapy|dual antiplatelet therapy (DAPT)]], or anticipated invasive or surgical procedures within the next 12 months, during which time [[Dual antiplatelet therapy|dual antiplatelet therapy (DAPT)]] may be interrupted.<ref name="pmid17291948">{{cite journal |author=Grines CL, Bonow RO, Casey DE, Gardner TJ, Lockhart PB, Moliterno DJ, O'Gara P, Whitlow P |title=Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians |journal=[[Journal of the American College of Cardiology]]|volume=49 |issue=6 |pages=734–9 |year=2007 |month=February |pmid=17291948|doi=10.1016/j.jacc.2007.01.003|url=http://linkinghub.elsevier.com/retrieve/pii/S0735-1097(07)00054-X|accessdate=2011-12-08}}</ref><ref name="pmid16860022">{{cite journal |author=Park DW, Park SW, Park KH, Lee BK, Kim YH, Lee CW, Hong MK, Kim JJ, Park SJ |title=Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up |journal=[[The American Journal of Cardiology]] |volume=98 |issue=3 |pages=352–6 |year=2006 |month=August |pmid=16860022|doi=10.1016/j.amjcard.2006.02.039|url=http://linkinghub.elsevier.com/retrieve/pii/S0002-9149(06)00720-X|accessdate=2011-12-08}}</ref><ref name="pmid16769908">{{cite journal |author=Spertus JA, Kettelkamp R, Vance C, Decker C, Jones PG, Rumsfeld JS, Messenger JC, Khanal S, Peterson ED, Bach RG, Krumholz HM, Cohen DJ |title=Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry|journal=[[Circulation]] |volume=113 |issue=24 |pages=2803–9 |year=2006 |month=June |pmid=16769908|doi=10.1161/CIRCULATIONAHA.106.618066 |url=http://circ.ahajournals.org/cgi/pmidlookup?view=long&pmid=16769908 |accessdate=2011-12-08}}</ref><ref name="pmid15926177">{{cite journal|author=Nasser M, Kapeliovich M, Markiewicz W |title=Late thrombosis of sirolimus-eluting stents following noncardiac surgery |journal=[[Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions]] |volume=65 |issue=4 |pages=516–9|year=2005 |month=August |pmid=15926177 |doi=10.1002/ccd.20391|url=http://dx.doi.org/10.1002/ccd.20391 |accessdate=2011-12-08}}</ref> ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])''<nowiki>"</nowiki>
| |
| |} | | |} |
|
| |
|
| {|class="wikitable"
| |
| |-
| |
| |colspan="1" style="text-align:center; background:LightCoral"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class III]] (No Benefit)
| |
|
| |
| |-
| |
| |bgcolor="LightCoral"|<nowiki>"</nowiki>'''1.''' PCI with [[stent|coronary stenting]] should not be performed if the patient is not likely to be able to tolerate and comply with [[Dual antiplatelet therapy|dual antiplatelet therapy (DAPT)]].<ref name="pmid17291948">{{cite journal |author=Grines CL, Bonow RO, Casey DE, Gardner TJ, Lockhart PB, Moliterno DJ, O'Gara P, Whitlow P |title=Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians |journal=[[Journal of the American College of Cardiology]] |volume=49 |issue=6 |pages=734–9 |year=2007 |month=February |pmid=17291948|doi=10.1016/j.jacc.2007.01.003|url=http://linkinghub.elsevier.com/retrieve/pii/S0735-1097(07)00054-X|accessdate=2011-12-08}}</ref><ref name="pmid9834303">{{cite journal |author=Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, Ho KK, Giambartolomei A, Diver DJ, Lasorda DM, Williams DO, Pocock SJ, Kuntz RE |title=A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators |journal=[[The New England Journal of Medicine]] |volume=339 |issue=23 |pages=1665–71 |year=1998 |month=December |pmid=9834303|doi=10.1056/NEJM199812033392303 |url=http://dx.doi.org/10.1056/NEJM199812033392303|accessdate=2011-12-08}}</ref><ref name="pmid17296821">{{cite journal |author=Mauri L, Hsieh WH, Massaro JM, Ho KK, D'Agostino R, Cutlip DE |title=Stent thrombosis in randomized clinical trials of drug-eluting stents |journal=[[The New England Journal of Medicine]] |volume=356 |issue=10|pages=1020–9 |year=2007 |month=March |pmid=17296821 |doi=10.1056/NEJMoa067731|url=http://dx.doi.org/10.1056/NEJMoa067731 |accessdate=2011-12-08}}</ref> ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])''<nowiki>"</nowiki>
| |
|
| |
| |-
| |
| |bgcolor="LightCoral"|<nowiki>"</nowiki>'''2.''' [[Drug eluting stent|Drug eluting stent (DES)]] should not be implanted if the patient is not likely to be able to tolerate and comply with prolonged [[Dual antiplatelet therapy|dual antiplatelet therapy (DAPT)]] or this cannot be determined before stent implantation.<ref name="pmid17291948">{{cite journal |author=Grines CL, Bonow RO, Casey DE, Gardner TJ, Lockhart PB, Moliterno DJ, O'Gara P, Whitlow P |title=Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians |journal=[[Journal of the American College of Cardiology]]|volume=49 |issue=6 |pages=734–9 |year=2007 |month=February |pmid=17291948|doi=10.1016/j.jacc.2007.01.003|url=http://linkinghub.elsevier.com/retrieve/pii/S0735-1097(07)00054-X|accessdate=2011-12-08}}</ref><ref name="pmid16860022">{{cite journal |author=Park DW, Park SW, Park KH, Lee BK, Kim YH, Lee CW, Hong MK, Kim JJ, Park SJ |title=Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up |journal=[[The American Journal of Cardiology]] |volume=98 |issue=3 |pages=352–6 |year=2006 |month=August |pmid=16860022|doi=10.1016/j.amjcard.2006.02.039|url=http://linkinghub.elsevier.com/retrieve/pii/S0002-9149(06)00720-X|accessdate=2011-12-08}}</ref><ref name="pmid16769908">{{cite journal |author=Spertus JA, Kettelkamp R, Vance C, Decker C, Jones PG, Rumsfeld JS, Messenger JC, Khanal S, Peterson ED, Bach RG, Krumholz HM, Cohen DJ |title=Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry|journal=[[Circulation]] |volume=113 |issue=24 |pages=2803–9 |year=2006 |month=June |pmid=16769908|doi=10.1161/CIRCULATIONAHA.106.618066 |url=http://circ.ahajournals.org/cgi/pmidlookup?view=long&pmid=16769908 |accessdate=2011-12-08}}</ref><ref name="pmid15926177">{{cite journal|author=Nasser M, Kapeliovich M, Markiewicz W |title=Late thrombosis of sirolimus-eluting stents following noncardiac surgery |journal=[[Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions]] |volume=65 |issue=4 |pages=516–9|year=2005 |month=August |pmid=15926177 |doi=10.1002/ccd.20391|url=http://dx.doi.org/10.1002/ccd.20391 |accessdate=2011-12-08}}</ref> ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])''<nowiki>"</nowiki>
| |
| |}
| |
| ==References== | | ==References== |
| {{reflist|2}} | | {{reflist|2}} |